DISCLAIMER Various statements in this presentation concerning Rocket's future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward- looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Al ...

Investor Presentation May 2025 1 Disclaimer This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking st ...

Results from A Phase 2, Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol (PB&TURSO) in Wolfram Syndrome (HELIOS) Lahar Mehta, MD Head of Global Clinical Development Amylyx Pharmaceuticals Additional Authors: Fumihiko Urano, MD, PhD; Stacy Hurst, RN, BSN, CDE; Bess Marshall, MD; Mathias Leinders, PhD; Nathalie Erpelding, PhD; Kelsi Cottrell; John Pesko, PhD 1 For scientific meeting use only. Do not duplicate, distribute, or disseminate. Copyright © 2024 Am ...

March 2025 © 2025 4D Molecular Therapeutics. All Rights Reserved. © 2025 4D Molecular Therapeutics. All Rights Reserved. Legal Disclaimer Barclays Global Healthcare Conference 2025 Corporate Presentation This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, strategy, future operations, future financial posi ...

Investor Presentation March 3, 2025 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's future financial performance, including its outlook and expected revenue for the year ended December 31, 2025; Cytek's business and operational goals and strategies; Cytek's business development plans; Cytek's product and application development plans; Cytek's market op ...

Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "expect", "anticipate", ...

Retina experience redefined Ocular Therapeutix Corporate Overview April 2025 Forward Looking Statements and Disclaimers Any statements in this presentation about future expectations, plans, and prospects for the Company, including the development and regulatory status of the Company's product candidates, including the design of, and the timing of the enrollment of the Company's SOL-1 and SOL-R Phase 3 clinical trials of AXPAXLI (also called OTX-TKI) for the treatment of wet AMD; the Company's plans to advan ...

INVESTOR PRESENTATION EXECUTING ON A PROVEN STRATEGY 1Q25 NYSE: HIW | #BETTERTOGETHER INVESTOR PRESENTATION FORWARD-LOOKING STATEMENTS Some of the information in this presentation may contain forward-looking statements. Such statements include, in particular, statements about our plans, strategies and prospects such as the following: the expected financial and operational results and the related assumptions underlying our expected results; the planned sales of non-core assets and expected pricing and impact ...

This presentation and the accompanying oral presentation, if any, contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of Health Catalyst, Inc. and its subsidiaries ("Health Catalyst" or the "Company"), market size and growth opportunities, competitive p ...

Redefining the Future of CAR T Doing What No CAR T Has Done Before Allogene Corporate Overview May 2025 Legal Disclaimers This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's ...